Compositions and methods for modulating immune responses
AssigneeZymoGenetics, Inc.
InventorsZeren Gao, Steven D. Levin, Janine Bilsborough, James W. West, Cameron S. Brandt, Frederick J. Ramsdell, Edward D. Howard, Eric M. Chadwick
Life of this patent
Estimating the term…
Abstract
The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
Claims24
(canceled)
An isolated zB7R1 polypeptide consisting of amino acid residues 16-140 of SEQ ID NO:2.
-11. (canceled)
A fusion protein comprising a polypeptide consisting of amino acid residues 16-140 of SEQ ID NO:2.
A formulation comprising:
- an isolated soluble polypeptide consisting of amino acid residues 16-140 of SEQ ID NO:2;
- and
- a pharmaceutically acceptable vehicle.
A formulation comprising:
- a fusion protein comprising a polypeptide consisting of amino acid residues 16-140 of SEQ ID NO:2;
- and
- a pharmaceutically acceptable vehicle.
Dependencies are inferred from the claim text.